Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The genetics of tumor suppression by p53

Award Number: R01CA279585
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 04/03/2023
PERIOD OF PERFORMANCE END DATE: 03/31/2028
AWARD TERMINATION DATE: 05/27/2025

Group Awards By:

View Award Description

The genetics of tumor suppression by p53 - Project Summary This submission represents a collaborative application from Maureen Murphy PhD at the Wistar Institute in Philadelphia and Kara Maxwell MD/PhD from the University of Pennsylvania Perelman School of Medicine. The goal is to study the function of a novel p53 mutation that was first discovered in several highly cancer- prone families seen in Dr. Maxwell’s clinic at the Hospital of the University of Pennsylvania. This variant, G334R in p53 protein (G331R in mouse p53) was found in nine different families with multiple cancers in multiple generations, including cousins with pediatric adrenal tumors; the latter are a hallmark of cancer- predisposing mutations in TP53. Moreover, we find that several tumors from these patients show loss of heterozygosity for p53. We show that the G334R variant is impaired for oligomerization, and for the induction of a small subset of p53 target genes, several of which are themselves tumor suppressors (PCLO, PLXNB3, and others). Our functional analyses of the G334R variant suggest that this is not a traditional Li Fraumeni mutant; that is, a mutation that completely inactivates p53 function. Rather, our functional data are most consistent with G334R being a p53 “hypomorph”, or a genetic variant that shows impaired, but not completely inactive, function. Specifically, 1) G334R possesses some ability to suppress colony formation in tumor cells, though it shows less ability than wild type p53; 2) G334R is fully capable of transactivating the overwhelming majority of p53-regulated genes, but is defective in the transactivation of approximately two dozen p53 target genes; 3) the peak incidence for breast cancer in G334R individuals is between the ages of 35-55, while most cases of Li Fraumeni occur between the ages of 20-40, and sporadic breast cancer peaks between the ages of 55- 75. The overarching goal of this proposal is to identify the mechanism(s) whereby G334R is impaired for function. In a completely unexpected finding, we show that there are some activities of the G334R hypomorph that are shared with two other cancer-predisposing p53 hypomorphs, P47S and Y107H. These activities include a heightened propensity to misfold into a conformation that is specific for mutant p53, as well as increased sensitivity to glutaminase inhibitors. We also show that using RNA sequencing data and machine learning approaches, we have identified a 42-gene signature that is predictive of a p53 hypomorph, and can distinguish a p53 hypomorph from WT p53 or a benign variant with 100% accuracy. The proposed research will help us better understand tumor suppression by p53, and to identify other carriers of hypomorphic genetic variants of p53.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $401,611 )
2026	2026	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	000	4	3/9/2026	NON-COMPETING CONTINUATION	$401,611
														Subtotal = $401,611

Issue Date FY: 2025 ( Subtotal = $401,611 )
2025	2025	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	001	3	5/27/2025	NON-COMPETING CONTINUATION	$40,160
2025	2025	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	000	3	3/17/2025	NON-COMPETING CONTINUATION	$361,451
2025	2024	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	002	2	5/27/2025	TERMINATION	$0
														Subtotal = $401,611

Issue Date FY: 2024 ( Subtotal = $454,267 )
2024	2024	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	002	2	9/16/2024	SUPPLEMENT FOR EXPANSION	$72,736
2024	2024	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	001	2	4/16/2024	NON-COMPETING CONTINUATION	$20,080
2024	2024	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	000	2	3/8/2024	NON-COMPETING CONTINUATION	$361,451
														Subtotal = $454,267

Issue Date FY: 2023 ( Subtotal = $422,186 )
2023	2023	THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY	3601 SPRUCE ST	PHILADELPHIA	PA	19104	PHILADELPHIA	USA	Cancer Biology Research	000	1	4/3/2023	NEW	$422,186
														Subtotal = $422,186

Grand Total All Awards = $1,679,675

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The genetics of tumor suppression by p53

Award Number: R01CA279585

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 04/03/2023

PERIOD OF PERFORMANCE END DATE: 03/31/2028

AWARD TERMINATION DATE: 05/27/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer